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B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28
to the Immunological Synapse
Despite the structural similarities between CD28 and
CTLA-4, their trafficking patterns and steady-state dis-
tributions within the cell are completely different. Recent
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studies have shown that prior to stimulation, CD28 isCancer Research Laboratory
uniformly distributed around the plasma membrane.Howard Hughes Medical Institute
However, when a T cell encounters an APC bearingUniversity of California, Berkeley
antigenic peptide-MHC complexes, CD28 concentratesBerkeley, California 94720
within the immunological synapse in less than a minute
(Egen and Allison, 2002). In contrast, CTLA-4 normally
resides in intracellular vesicles at the back of the migrat-Summary
ing T cell. Upon engagement of the TCR, these intracellu-
lar vesicles re-orient toward the APC with a fraction ofThe reported affinity differences between CD28 and
CTLA-4 eventually localizing to the synapse (Egen andCTLA-4 binding to B7-1 and B7-2 may serve to selec-
Allison, 2002). Interestingly, the amount of CTLA-4 thattively regulate CD28 and CTLA-4 function by differen-
translocates to the synapse correlates with the strengthtially recruiting and/or stabilizing these molecules at
of the TCR signal, suggesting that CTLA-4 might prefer-the immunological synapse. Here we show that ligand
entially restrict T cell responses to stronger TCR signalsbinding is important for the accumulation of both CD28
(Egen and Allison, 2002; Egen et al., 2002).and CTLA-4 at the synapse. While CD28 is recruited to
The goal of our studies was to determine the require-the synapse in the absence of B7-1 and B7-2 binding, it
ments for CD28 and CTLA-4 concentration at the syn-is not effectively stabilized there, as its localization
apse. We and others have previously shown that expres-can be disrupted by CTLA-4. In the case of CTLA-4,
sion of B7-1 and/or B7-2 on the APC is insufficient toligand binding is critical for its concentration at the
induce redistribution of CD28 or CTLA-4 upon contactsynapse. We also demonstrate that the affinity and
with a T cell: TCR signaling is required (Bromley et al.,avidity differences in ligand binding translate into se-
2001; Egen and Allison, 2002). A question that arises islective recruitment of CD28 or CTLA-4 to the immuno-
whether ligand binding is then necessary for concentrat-logical synapse—B7-1 is the major ligand mediating
ing CD28 and CTLA-4 at the synapse. This question isCTLA-4 localization, while B7-2 is the main ligand for
especially relevant in light of the recent discovery ofCD28 concentration at the synapse.
CD28 and CTLA-4 isoforms that lack extracellular do-
mains and thus function in a ligand-independent mannerIntroduction
(Hanawa et al., 2002; Ueda et al., 2003; Vijayakrishnan et
al., 2004). Because the ligand-independent CD28 forms
 T cell activation depends on the recognition of spe-
heterodimers with the full-length protein, it was as-
cific antigenic peptides bound to major histocompatibil-
sumed to act exclusively as an amplifier of signals gener-
ity complex (MHC) molecules on the surface of antigen-
ated by the full-length CD28 (Hanawa et al., 2002). In
presenting cells (APC) by the T cell receptor (TCR). TCR contrast, the ligand-independent CTLA-4 isoform by it-
engagement alone, however, is insufficient for T cell self might be capable of generating a negative signal in
activation and can instead trigger apoptosis or a state of T cells (Vijayakrishnan et al., 2004).
antigen-specific nonresponsiveness (anergy) (Schwartz, The experiments presented here demonstrate that li-
1990). In addition to TCR ligation, optimal T cell prolifera- gand binding is important for the localization of full-
tion and acquisition of effector functions require signals length mouse CD28 and CTLA-4 to the immunological
by the costimulatory molecule CD28. Upon binding to its synapse. In the case of CD28, a mutant that failed to
ligands, B7-1 (CD80) and B7-2 (CD86), CD28 enhances bind B7-1 and B7-2 concentrated at the synapse of
T cell proliferation by increasing the transcription and fewer conjugates than the wild-type (wt) molecule. This
the mRNA stability of interleukin-2 (IL-2), as well as by accumulation defect was alleviated by the presence of
upregulating the antiapoptotic protein Bcl-XL (reviewed endogenous wt CD28 and was exacerbated by high
in Acuto and Michel, 2003). A closely related molecule, levels of CTLA-4. The analogous CTLA-4 mutant failed
cytotoxic T lymphocyte antigen 4 (CTLA-4) (Brunet et to localize to the immunological synapse even in the
al., 1987), binds to the same ligands as CD28 with much presence of endogenous wt CTLA-4. Using APC ex-
higher affinity (Collins et al., 2002; Linsley et al., 1994). pressing only single ligands, we found that B7-2 is the
In contrast to CD28, CTLA-4 restricts T cell activation, primary ligand responsible for CD28 concentration at
as indicated by the fact that CTLA-4 ligation inhibits the synapse, while B7-1 is the principal ligand mediating
IL-2 production, IL-2 receptor expression, and cell cycle CTLA-4 localization to the synapse. These results are
progression and that CTLA-4-deficient mice die of a consistent with physicochemical studies that found
lymphoproliferative disorder within 3–4 weeks of age large avidity differences among the various human re-
(reviewed in Egen et al., 2002). ceptor/ligand combinations and predicted that the ratio
of engaged CD28 to engaged CTLA-4 in the synapse will
be higher when B7-2 is expressed on the APC relative*Correspondence: allisonj@mskcc.org
to when B7-1 is expressed (Collins et al., 2002). Our1Present address: Memorial Sloan-Kettering Cancer Center, New
York, New York 10021. experiments verify this hypothesis and show that the
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reported affinity differences in ligand binding translate onstrate that in our system, mutation of the second
into selective recruitment of CD28 or CTLA-4 to the tyrosine in the MYPPPY ligand binding motif of both
immunological synapse. CD28 and CTLA-4 abolishes binding to B7-1 and B7-2.
Results Mutation of Y123A Interferes with CD28
Concentration at the Immunological Synapse
MYPPPY Mutations Affect CD28 and CTLA-4 To determine whether ligand binding is required for
Binding to B7-1Ig and B7-2Ig CD28 concentration at the immunological synapse, wt
To evaluate the ligand binding requirements for mouse CD28-CFP or CD28-Y123A-CFP were introduced into
CD28 and CTLA-4 concentration at the synapse, the previously activated primary 5C.C7 CD28/ T cells via
second tyrosine in the MYPPPY motif of both molecules retroviral infection. To determine whether CTLA-4 af-
was mutated to an alanine (Y123A for CD28 and Y139A fects the synaptic concentration of either molecule, the
for CTLA-4). Previous studies have shown that this mu- cells were also infected with viruses expressing wt
tation abolishes CD28Ig and CTLA-4Ig binding to B7-1- CTLA-4-YFP. The T cells were allowed to form conju-
transfected Chinese hamster ovary cells and in surface gates with peptide-pulsed CH12.Lx cells for 20 min.
plasmon resonance (SPR) measurements eliminated Conjugates were selected on the basis of protein kinase
CTLA-4Ig binding to both B7-1Ig and B7-2Ig (Morton et C- (PKC ) accumulation at the T cell-APC interface
al., 1996; Peach et al., 1994). However, it was also re- because PKC  localizes specifically to the center of the
ported that the Y123A mutation in CD28 made no differ- immunological synapse (Monks et al., 1998). In these
ence in the binding of B7-1Ig and only reduced binding experiments, CD28-CFP concentrated at the synapse
of B7-2Ig in experiments using L cell transfectants (Kariv of 93% (99 of 106) of the cells (Figure 2A). The fact that
et al., 1996). CD28-CFP did not completely cluster at the synapse
To determine whether the Y123A mutation interferes (some was present in the rest of the plasma membrane)
with ligand binding in our system, previously activated might be due to its overexpression. However, the fact
5C.C7 CD28/ T cells were infected with retroviral vec- that this was observed when either CH12.Lx or lipopoly-
tors encoding either wt CD28-YFP or CD28-Y123A-YFP saccharide (LPS)-activated B6 B cells were used as APC
and stained with anti-CD28 antibodies or B7-1Ig or (below), despite the fact that the levels of B7-1 and B7-2
B7-2Ig. The left panel of Figure 1A shows that while on these cells differ by a factor of 5 to 7 (data not shown),
both infected populations expressed comparable levels suggests that B7-1 and B7-2 are not limiting. The re-
of CD28 at the plasma membrane, the Y123A mutant mainder of the conjugates had no detectable accumula-
failed to bind detectable amounts of soluble B7-1 or tion of CD28-CFP—it appeared uniformly distributed
B7-2 (Figure 1A, center and right panels). The surface around the plasma membrane (Figure 2B). In contrast,
levels of the exogenous molecules were 3–4 times higher CD28-Y123A-CFP concentrated at the synapse of only
than the levels of endogenous CD28 in activated wt 25% (25 of 100) of 5C.C7 CD28/ T cells (Figure 2C).
5C.C7 T cells (data not shown). In the majority of the conjugates (56%, 56 of 100), the
Similar results were obtained when 5C.C7 CD28/ mutant CD28 was uniformly distributed around the
T cells were infected with viruses encoding either wt or
plasma membrane (Figure 2D), while 19% (19 of 100) of
Y139A CTLA-4-YFP. In these cells, the plasma mem-
the conjugates had excluded CD28-Y123A-CFP from
brane levels of CTLA-4 were 2–4 times higher than the
the site of CTLA-4-YFP accumulation (Figure 2E). Theselevels in uninfected 5C.C7 T cells (data not shown). De-
results indicate that ligand binding is not absolutely re-spite the expression of only three times more CTLA-4
quired for CD28 recruitment to the synapse, but it facili-on the surface, as revealed by anti-CTLA-4 antibody
tates its concentration there.staining (Figure 1B, left panel), B7-1Ig staining of wt
The equivalent series of experiments in wt 5C.C7 cellsCTLA-4-YFP-expressing cells was 22-fold higher than
yielded similar results. Fully 97% (97 of 101) of the conju-that of CTLA-4-Y139A-infected cells (Figure 1B, center
gates had accumulated wt CD28-CFP, while the remain-panel). In contrast, the difference in B7-2Ig binding to
der had uniform CD28-CFP distribution around thecells expressing wt or Y139A CTLA-4-YFP was compa-
plasma membrane. In contrast, 40% (40 of 100) of therable to the difference in antibody binding to surface
T cells had concentrated CD28-Y123A-CFP at the syn-wt or mutant CTLA-4 (Figure 1B, right panel), possibly
apse, almost double the number obtained in CD28-defi-because of low CTLA-4 levels at the plasma membrane.
cient T cells. This result suggests that the endogenousAs CTLA-4 is known to primarily localize to intracellular
wt CD28 facilitates the concentration of CD28-Y123A-vesicles rather than the cell surface, these experiments
CFP at the synapse. Forty-seven percent (47 of 100) ofwere repeated using wt and Y139A CTLA-4-YFP in which
the conjugates had uniformly distributed CD28-Y123A-Tyr201, a critical residue in the intracellular localization
CFP, while 13% (13 of 100) had excluded the mutantmotif, had been mutated to Phe. This mutation stabilizes
CD28 from the site of CTLA-4 concentration. These re-CTLA-4 at the plasma membrane by abrogating binding
sults are summarized in the left panels of Figure 2F.of the clathrin adaptor AP-2 (Baroja et al., 2002). As
To determine whether CTLA-4 affects the concentra-expected, T cells infected with viruses expressing both
tion of the wt or the mutant CD28, conjugates were alsowt and Y139A CTLA-4-YFP carrying this mutation had
selected on the basis of CTLA-4 accumulation at themuch higher surface levels of CTLA-4 than the original
synapse. The data are summarized in the right panelsmolecules (left panels of Figure 1C versus Figure 1B).
of Figure 2F. In 5C.C7 CD28/ T cells, 90% (103 of 114)Despite this high expression level, CTLA-4-Y139A-YFP
of the conjugates with concentrated CTLA-4-YFP hadfailed to bind significant amounts of B7-1Ig or B7-2Ig
(Figure 1C, center and right panels). These results dem- also accumulated wt CD28-CFP at the synapse. In con-
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Figure 1. MYPPPY Mutations Affect CD28 and CTLA-4 Binding to B7-1Ig and B7-2Ig
5C.C7 CD28/ T cells were infected with either wt (solid line) or mutant (dotted line) CD28 (A) or CTLA-4 (B and C). Infected 5C.C7 CD28/
cells that did not express YFP were used as a negative control (shaded histogram). Anti-CD28 or anti-CTLA-4 antibodies were used to
determine protein surface levels (left panels). Cells were also stained with B7-1Ig (middle panels) and B7-2Ig (right panels) to evaluate the
relative ligand binding capability of the wt and mutant proteins. Both the wt and the mutant CTLA-4 molecules in C contain Y201F mutations,
which increase the plasma membrane levels of both proteins.
trast, only 8% (8 of 104) of the conjugates with concen- trated CTLA-4. The majority (63%, 66 of 104) of the
remaining conjugates had uniformly distributed CD28-trated CTLA-4-YFP at the synapse concentrated CD28-
Y123A-CFP. This is approximately one-third of the num- Y123A-CFP, while 29% (30 of 104) had depleted CD28-
Y123A from the site of CTLA-4 concentration.ber of conjugates that accumulated the mutant CD28
when PKC -positive conjugates were counted, sug- In the studies above, the cells expressed high levels
of exogenous CTLA-4-YFP, which could affect CD28-gesting that CTLA-4 can interfere with the concentration
of the mutant CD28 at the synapse but not with the Y123A concentration at the synapse. To determine what
happens when CTLA-4 is not overexpressed, experi-accumulation of the wt molecule. It is also possible,
however, that these differences represent the heteroge- ments were also conducted using wt or CD28/ 5C.C7
cells that were infected with viruses encoding lck-YFPneous nature of T cell activation, so that the cells with
concentrated PKC  are inherently more capable of re- (Straus and Weiss, 1992) and either the wt or the mutant
CD28 constructs described above. Conjugates were se-cruiting the mutant CD28 than the cells with concen-
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Figure 2. Ligand Binding Is Required for CD28 Concentration at the Immunological Synapse
5C.C7 CD28/ T cells were co-infected with wt CTLA-4-YFP and wt CD28-CFP (A and B) or CD28-Y123A-CFP (C, D, and E). Conjugates
between MCC-pulsed CH12.Lx cells and infected T cells that had concentrated PKC  (blue) at the synapse were scored for localization of
wt or mutant CD28-CFP (green) to the synapse. CTLA-4-YFP is in red. Representative cells with concentrated wt or mutant CD28 are shown
in (A) and (C), while cells with uniform distribution of wt or mutant CD28 are shown in (B) and (D). The cell in (E) is an example where CD28-
Y123A is depleted from the site of CTLA-4 concentration. The insets in the top left of the images show the interface between the two cells
at a higher magnification. The statistics from three experiments with at least 30 conjugates, both in 5C.C7 wt and CD28/ T cells, are shown
in (F). Error bars represent standard deviation between experiments.
lected on the basis of the synaptic concentration of lck- CD28/ T cells were co-infected with viruses express-
ing CD28-YFP and CD28-Y123A-CFP. Fifty-six percentYFP and were subsequently scored for either CD28-CFP
or CD28-Y123A-CFP accumulation at the synapse. In (57 of 101) of the conjugates with concentrated wt CD28
also concentrated the mutant CD28-Y123A (Figure 4A),both 5C.C7 wt and CD28/ cells, 100% of the conju-
gates with concentrated lck-YFP (93 for wt and 91 for suggesting that at least some of the effect in 5C.C7 wt
T cells might be due to heterodimerization. The rest ofCD28/ cells) also concentrated wt CD28-CFP at the
synapse (Figure 3A). In contrast, only 42% (56 of 133) of the conjugates had uniform CD28-Y123A despite the
concentration of wt CD28 (Figure 4B). Furthermore,the conjugates with concentrated lck-YFP accumulated
the mutant CD28-Y123A-CFP in 5C.C7 CD28/ cells, when the same experiments were performed in wt 5C.C7
cells, a significantly higher fraction (88%, 91 of 103) ofwhile a significantly higher fraction (92%, 93 out of 101)
concentrated the mutant CD28-Y123A-CFP in wt 5C.C7 the conjugates concentrated both the wt and the mutant
CD28, presumably because the additional endogenouscells (Figure 3B). The remainder of the conjugates had
uniform distribution of CD28-Y123A-CFP around the wt CD28 heterodimerized with CD28-Y123A-CFP and
recruited it to the synapse. It is also possible, however,plasma membrane (Figure 3C). The results are summa-
rized in Figure 3D. These data show that while the mutant that the wt CD28 facilitated the generation of a stable
synapse either because of its physical properties orCD28 can localize to the synapse in a significant number
of cells, it does so less readily than wt CD28, indicating because of active signaling. These results are summa-
rized in Figure 4C. Taken together, the data suggest thatan important role for ligand binding in receptor recruit-
ment. Overexpression of CTLA-4 reduces the degree of CD28 can concentrate at the immunological synapse in
the absence of ligand; however, B7-1 or B7-2 bindingmutant CD28 localization to the synapse even further,
suggesting that CTLA-4 may either physically displace stabilizes CD28 at the synapse, either because the li-
gands prevent the diffusion of CD28 away from the inter-the mutant CD28 or actively reduce its recruitment by
generating inhibitory signals. face or because they trigger a signaling cascade.
To examine whether the higher fractions of conjugates
with concentrated CD28-Y123A-CFP in wt 5C.C7 versus Mutation of Y139A Inhibits CTLA-4 Localization
to the Immunological Synapse5C.C7 CD28/ T cells (Figure 2F and 3D) might be due
to the formation of heterodimers composed of endoge- To determine whether ligand binding is required for
CTLA-4 localization to the immunological synapse,nous CD28 and exogenous mutant CD28-Y123A, 5C.C7
Role of B7 in Synapse Localization of CD28/CTLA-4
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Figure 3. In the Absence of High CTLA-4 Levels, Ligand Binding Is Important for CD28 Accumulation at the Synapse, but It Is Not Abso-
lutely Required
5C.C7 CD28/ T cells were co-infected with lck-YFP and wt CD28-CFP (A) or CD28-Y123A-CFP (B and C). Conjugates between MCC-pulsed
CH12.Lx cells and infected T cells that had concentrated lck-YFP (red) at the synapse were scored for localization of wt or mutant CD28-
CFP (green) to the synapse. PKC  is in blue. Representative cells with concentrated wt or mutant CD28 are shown in (A) and (B), while a cell
with uniform distribution of mutant CD28 is shown in (C). The statistics from three experiments with at least 30 conjugates per experiment,
both in 5C.C7 wt and CD28/ T cells, are shown in (D). Error bars represent standard deviation between experiments.
5C.C7 wt T cells expressing either wt CTLA-4-YFP or localized wt CTLA-4-YFP to the immunological synapse
(Figure 5A). In the remainder of the conjugates, CTLA-4CTLA-4-Y139A-YFP, in addition to CD28-CFP, were
compared. When conjugates were selected on the basis was only present in intracellular vesicles (Figure 5B). In
contrast, CTLA-4-Y139A-YFP was concentrated at theyof PKC  accumulation, 92% (93 of 101) of the cells
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Figure 4. Wt CD28 Facilitates the Concentration of the Mutant CD28 at the Synapse
5C.C7 CD28/ T cells were co-infected with CD28-YFP and CD28-Y123A-CFP (A and B). Conjugates between MCC-pulsed CH12.Lx cells
and infected T cells that had concentrated CD28-YFP (red) at the synapse were scored for localization of CD28-Y123A-CFP (green) to the
synapse. PKC  is in blue. A representative cell with concentrated mutant CD28 is shown in (A), while a cell with uniform distribution of CD28-
Y123A is shown in (B). The statistics from three experiments with at least 30 conjugates, both in 5C.C7 wt and CD28/ T cells, are shown
in (C). Error bars represent standard deviation between experiments.
synapse of only 14% (14 of 101) of the conjugates (Figure CTLA-4. The results for CTLA-4-Y139A in CD28-positive
conjugates were similar to those in PKC -positive ones5C), while the remaining 86% (87 of 101) had CTLA-4-
Y139A-YFP in intracellular vesicles (Figure 5D). The and are summarized in the right panel of Figure 5E.
They demonstrate that ligand binding is critical for theresults from the analogous studies in 5C.C7 CD28/
T cells were very similar (Figure 5E, left panel) and indi- localization of CTLA-4 to the synapse.
cate that ligand binding is critical for CTLA-4 localization
to the immunological synapse. B7-2 Is the Major Ligand Mediating CD28
Concentration at the Synapse, while B7-1 Is the MainWhen conjugates were selected on the basis of CD28-
CFP concentration at the synapse, wt CTLA-4-YFP ac- Ligand for CTLA-4 Localization to the Synapse
The studies described above established that ligandcumulated in a smaller fraction of cells relative to the
numbers for the PKC -positive conjugates. This finding binding is important for CD28 and CTLA-4 concentration
at the immunological synapse. However, the use of mu-could result from differences in the kinetics of CD28 and
PKC  accumulation at the synapse, with the timing tants that completely abolished ligand binding (Figure
1) did not allow us to address the issue of potentialof PKC  recruitment more closely following that of
Role of B7 in Synapse Localization of CD28/CTLA-4
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Figure 5. Ligand Binding Is Critical for CTLA-4 Localization to the Immunological Synapse
5C.C7 wt T cells were co-infected with wt CD28-CFP and wt CTLA-4-YFP (A and B) or CTLA-4-Y139A-YFP (C and D). Conjugates between
MCC-pulsed CH12.Lx cells and infected T cells that had concentrated PKC  (blue) at the synapse were scored for localization of wt or mutant
CTLA-4-YFP (red) to the synapse. CD28-CFP is in green. Representative cells with concentrated wt or mutant CTLA-4 are shown in (A) and
(C), while cells in which wt or mutant CTLA-4 localized only to intracellular vesicles are shown in (B) and (D). The statistics from three
experiments with at least 30 conjugates, both in 5C.C7 wt and CD28/ T cells, are shown in (E). Error bars represent standard deviation
between experiments.
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Figure 6. B7-2 Is the Major Ligand for CD28 Concentration at the Synapse
OTII T cells were co-infected with CD28-CFP and CTLA-4-YFP. Conjugates between OVA-pulsed B cells from B6 wt (A and B), B7-1/ B7-2/
(C and D), B7-1/ (E and F) or B7-2/ (G and H) and infected T cells that had concentrated PKC  (blue) at the synapse were scored for
CD28 (green) localization. CTLA-4 is in red. Representative cells with concentrated CD28 are shown in (A), (C), (E), and (G), while cells with
uniform distribution of CD28 are shown in (B), (D), (F), and (H). The statistics from three experiments with at least 30 conjugates are shown
in (I). Error bars represent standard deviation between experiments.
differences between B7-1 and B7-2 with respect to re- centrated CD28 was only determined in PKC -positive
conjugates. In this case, 46% (47 of 102) of the cellscruitment of CD28 and CTLA-4 to the synapse. To this
end, we investigated CD28 and CTLA-4 localization at concentrated CD28 (Figure 6C), while the rest had uni-
formly distributed CD28 (Figure 6D). This number is simi-the synapse using LPS-activated B cells from wt,
B7-1/, B7-2/, or B7-1/B7-2/ mice as APC. The lar to that obtained for CD28-Y123A accumulation in
CD28-deficient 5C.C7 T cells in the absence of CTLA-4B cells had to be LPS activated because they do not
express B7-1 until 48 hr post stimulation (Lenschow et overexpression (Figure 3D), again indicating that CD28
can concentrate at the synapse in the absence of ligand,al., 1993). The activated B7-1/ and B7-2/ B cells had
comparable surface levels of B7-2 and B7-1, respec- but not as well as when B7-1 and B7-2 are present.
When B7-1-deficient B cells were used as APC, thetively, to wt B cells. Assuming similar affinities for the
anti-B7-1 and anti-B7-2 antibodies used, cells ex- results resembled those for the wt B cells. Eighty-nine
percent (92 of 102) of the conjugates with concentratedpressed twice as much B7-2 as they did B7-1 (data not
shown). Because the B7-deficient animals were on the PKC  at the synapse and 92% (92 of 100) of the cells
with CTLA-4 at the synapse had also concentrated CD28B6 instead of the B10.A background, we used T cells
from OTII TCR transgenic mice rather than 5C.C7. (Figure 6E), suggesting that B7-1 was not required for
CD28 accumulation at the interface. The remaining cellsIn order to determine the ligand requirements for CD28
concentration at the synapse, conjugates were selected had uniformly distributed CD28 (Figure 6F). In contrast,
when B7-2-deficient B cells were used as APC, onlyon the basis of either PKC  or CTLA-4 accumulation at
the T cell-APC interface and the results were compared. 60% (61 of 102) of the conjugates with concentrated
PKC  and 45% (45 of 100) of the cells with concentratedWhen wt B6 B cells were used as APC, CD28 accumu-
lated in 89% (92 of 103) of conjugates with concentrated CTLA-4 had also concentrated CD28 (Figure 6G). The
data are summarized in Figure 6H. They indicate thatPKC  and in 88% (88 of 100) of the cells if they were
selected on the basis of CTLA-4 accumulation (Figure B7-2 is the ligand primarily responsible for CD28 con-
centration at the synapse and suggest that CTLA-4 can6A). These numbers are comparable to those obtained
in the studies of 5C.C7 T cells above. The rest of the outcompete CD28 for binding to B7-1.
When the reciprocal series of experiments were per-conjugates had CD28 uniformly distributed around the
plasma membrane, despite the concentration of both formed, wt B6 B cells were found to induce CTLA-4
accumulation at the synapse of 77% (79 of 103) of thePKC  and CTLA-4 (Figure 6B). Because too few conju-
gates localized CTLA-4 to the synapse in experiments conjugates with concentrated PKC  and 67% (82 of
123) of those with concentrated CD28 (Figure 7A). Thesewith B7-1/B7-2/ B cells as APC, the fraction of con-
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Figure 7. B7-1 Is the Major Ligand for CTLA-4 Concentration at the Synapse
OTII T cells were co-infected with CD28-CFP and CTLA-4-YFP. Conjugates between OVA-pulsed B cells from B6 wt (A and B), B7-1/B7-2/
(C and D), B7-1/ (E and F), or B7-2/ (G and H) and infected T cells that had concentrated PKC  (blue) at the synapse were scored for
CTLA-4 (red) localization. CD28 is in green. Representative cells with concentrated CTLA-4 are shown in (A), (C), (E), and (G), while cells in
which CTLA-4 localized only to intracellular vesicles are shown in (B), (D), (F), and (H). The statistics from three experiments with at least 30
conjugates are shown in (I). Error bars represent standard deviation between experiments.
numbers are somewhat lower than the ones obtained in both B7-1 and B7-2. These data are summarized in Fig-
ure 7I. These results clearly indicate that B7-1 is thethe studies of 5C.C7 T cells and CH12.Lx APC, probably
because the B6 B cells expressed lower levels of B7-1 preferred ligand for CTLA-4 localization to the synapse.
and B7-2 than the B cell lymphoma (data not shown).
In the conjugates in which CTLA-4 was not concentrated Discussion
with PKC  and CD28 at the synapse, it was still evident
in intracellular vesicles (Figure 7B). When B cells defi- The goal of our study was to determine whether ligand
binding is important for CD28 and CTLA-4 localizationcient for both B7-1 and B7-2 were used as APC, CTLA-4
localized to the synapse of only 16% (16 of 102) of the patterns and whether the differential affinities of CD28
and CTLA-4 for their ligands translate into selective re-PKC -positive and 15% (15 of 100) of the CD28-positive
conjugates (Figure 7C). These numbers are similar to cruitment of the molecules to the immunological syn-
apse. Two independent lines of investigation demon-those obtained for the mutant CTLA-4-Y139A in 5C.C7
T cells. The rest of the conjugates had CTLA-4 in intracel- strated that B7-1 or B7-2 binding is important for CD28
concentration at the synapse, but it is not absolutelylular vesicles, despite the concentration of both PKC 
and CD28 at the synapse (Figure 7D), indicating that required. When the APC lacked both ligands, CD28 ac-
cumulated at the synapse of half as many conjugatesligand binding is critical for CTLA-4 localization to the
synapse. We noted, however, that conjugates with con- as when the APC expressed B7-1 and B7-2 (Figure 6).
In addition, the ligand binding mutant of CD28 concen-centrated PKC  and CD28 seemed less prevalent when
the B7-1/B7-2/ cells were used as APC instead of wt trated at the synapse of fewer cells than the wt molecule,
especially in the presence of high levels of CTLA-4 (Fig-B6 B cells, although this effect was difficult to quantify.
When B7-1-deficient B cells were used as APC, CTLA-4 ures 2 and 3). These results indicate that while CD28
can concentrate at the synapse in the absence of B7-1localized to the synapse in only 31% (32 of 102) of the
PKC -positive and in 28% (28 of 100) of the CD28- and B7-2, ligand binding plays an important role in regu-
lating its localization during T cell-APC interactions.positive conjugates (Figure 7E), and the majority of the
conjugates in both cases had CTLA-4 in intracellular Data from multiple studies imply that CD28 recruit-
ment to the immunological synapse is initiated by TCRvesicles (Figure 7F). In contrast, when B7-2/ B cells
were used as APC, CTLA-4 localized to the synapse of signaling, probably as a result of the reorganization of
the actin cytoskeleton. B7-1 and B7-2 binding could75% (76 of 102) of the PKC -positive and 70% (70
of 100) of the CD28-positive conjugates (Figure 7G), a stabilize CD28 that has been recruited to the synapse
either by preventing its diffusion away from the T cell-frequency close to that obtained with wt cells expressing
Immunity
410
APC contact site or by the generation of a signal that could by themselves result in differential binding and
distinct functional consequences.further alters actin dynamics and leads to greater CD28
Nevertheless, early studies demonstrated that block-accumulation at the synapse via a positive-feedback
ing B7-2 on B cells with specific antibodies preventsmechanism. The ligand binding mutant of CD28 may
T cell proliferation, while anti-B7-1 antibodies have noeither diffuse away from the synapse or fail to generate
effect (Hathcock et al., 1994). In addition, in severalthis potential retention signal. The presence of high lev-
mouse models of autoimmunity, administration of anti-els of CTLA-4 may further enhance this effect by either
B7-2, but not anti-B7-1, blocking antibodies correlatesphysically displacing the ligand binding mutant or damp-
with amelioration of disease (Lenschow et al., 1995; Na-ening signals required for its retention.
kajima et al., 1995; Peterson et al., 1999; Saegusa et al.,While ligand binding affects CD28 localization only
2000). In addition, B7-2-deficient animals are protectedmoderately, the presence of B7-1/B7-2 appears to be
from some autoimmune diseases, while B7-1-deficienta critical factor regulating recruitment of CTLA-4 to the
mice are more susceptible (Girvin et al., 2000; Liang etsynapse. When it could not bind ligand, either because
al., 1999). Furthermore, anti-B7-2 antibodies interfereof the ligand binding domain mutation (Figure 5) or be-
with the expansion of adoptively transferred T cellscause of absence of B7-1 and B7-2 on the APC (Figure
(Kearney et al., 1995), prolong allograft survival (Judge7), CTLA-4 accumulated at the synapse in a significantly
et al., 1999), and enhance suppression by CD4CD25smaller fraction of conjugates than when it could bind
regulatory T cells (Zheng et al., 2004), while anti-B7-1ligand. CTLA-4 that localized to the synapse under con-
antibodies have the opposite effect. However, severalditions where ligand binding was not possible could
in vivo studies contradict the paradigm that B7-1 isrepresent a transient population of molecules recently
mostly inhibitory while B7-2 is activating (Kuchroo etdelivered to the synapse from intracellular vesicles as
al., 1995; Li et al., 2000; Miller et al., 1995; Silver et al.,a result of TCR signaling. Alternatively, this CTLA-4
2000). These conflicting sets of data may be the resultmight be derived from a putative small population of
of changes in the Th1/Th2 balance that affect diseasemolecules present on the cell surface prior to conjugate
outcome or differential expression of B7-1 and B7-2 onformation that is recruited to the synapse by the same
target cells (Salomon and Bluestone, 2001). The majorityactin-based mechanism that recruits CD28. Our finding
of the reports, however, as well as our own data, supportthat ligand binding is required for CTLA-4 localization
a model where B7-1 preferentially binds CTLA-4 and asat the synapse brings into question the mechanism by
a consequence inhibits T cell function, while by beingwhich the ligand-independent CTLA-4 isoform might in-
the favored CD28 ligand, B7-2 can effectively promotehibit T cell function independently of the full-length mol-
T cell responses (Sansom et al., 2003). However, theecule (Vijayakrishnan et al., 2004). Future studies should
fact that B7-1 knockout mice do not suffer from theaddress whether the trafficking pattern or the intracellu-
lymphoproliferative syndrome that afflicts CTLA-4-defi-lar localization of ligand-independent molecules in pri-
cient mice underscores the fact that this preferencemary T cells differ from those of the full-length proteins.
is not absolute, and that B7-2/CTLA-4 binding can beOur experiments with the B7-1- and B7-2-deficient
sufficient to prevent lymphoproliferation (Borriello et al.,APC clearly demonstrate distinct ligand preferences for
1997; Freeman et al., 1993).CD28 and CTLA-4 localization to the synapse. CD28
Recently, several groups have provided a mechanismconcentrated at the synapse equally well when the APC
for differential binding of CD28 and CTLA-4 to B7-1 andexpressed both ligands or had only B7-2, but poorly
B7-2, which derives from structural and physicochemi-when the APC expressed only B7-1 (Figure 6). The im-
cal experiments. Three crystallographic studies havepaired synaptic localization of CD28 observed with APC
shown that both in the case of human and mouse mole-expressing only B7-1 was even more pronounced when
cules, the two ligand binding domains of a CTLA-4 dimerCTLA-4 was present at the synapse, suggesting that
lay distal to the dimerization interface, and as a result
CTLA-4 effectively competes with CD28 for B7-1 bind-
could promote the formation of a periodic structure
ing. Together, the data demonstrate that B7-2 is the
where one CTLA-4 dimer binds two dimers of B7-1 or
preferred ligand for concentrating CD28 at the synapse. B7-2. These proteins could then extend the hypothetical
The results for CTLA-4 were exactly the opposite. protein lattice further by binding additional CTLA-4 mol-
CTLA-4 localized to the synapse of the same fraction ecules (Ostrov et al., 2000; Schwartz et al., 2001;
of conjugates when the APC expressed both ligands or Stamper et al., 2001). Subsequent crystallographic data,
had only B7-1, but very poorly when the APC expressed however, suggested that unlike human B7-1, human
only B7-2 (Figure 7). These results clearly show that B7-2 is monomeric (Zhang et al., 2003). In addition, re-
B7-1 is the preferred ligand for CTLA-4 accumulation in cent SPR measurements using human proteins demon-
the synapse. strated that while B7-2 exists as monomers, B7-1 tends
Our work demonstrates that B7-1 and B7-2 preferen- to form dimers and that with respect to B7 binding, CD28
tially recruit CTLA-4 and CD28, respectively, to the im- homodimers are monovalent, while CTLA-4 dimers are
munological synapse and as a result may differentially divalent (Collins et al., 2002). This study demonstrated
promote inhibition or activation of T cell functions. This that B7-1 markedly favors binding to CTLA-4 over CD28,
was previously suggested based on the delayed surface while B7-2 displays much less bias. Thus, the ratio of
expression of B7-1 relative to B7-2 (Lenschow et al., engaged CD28 to engaged CTLA-4 at the T cell-APC
1993), coupled with the delayed expression of CTLA-4 interface will likely be higher when B7-2 is present on
relative to CD28 (Linsley et al., 1992). However, since all the APC relative to when B7-1 is expressed (Collins et
four molecules are expressed after activation, it seems al., 2002). Our own experiments show that B7-2 prefer-
entially concentrates CD28 at the immunological syn-unlikely that simple differences in expression kinetics
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CFP/YFP Fusion Constructs and Retrovirusesapse while B7-1 favors the synaptic localization of
C-terminal fusions of mouse CD28, CTLA-4, and lck to CFP andCTLA-4, indicating that the differences predicted by the
YFP were generated via PCR that deleted their stop codons andbinding studies are realized in the assembly of the syn-
introduced a 50-amino-acid flexible linker (10x Ser1Gly4) betweenapse: while both CD28 and CTLA-4 can bind B7-1 and the proteins and the fluorescent tags. The point mutations in the
B7-2, the stronger avidity of CTLA-4 for B7-1 leaves only MYPPPY ligand binding motif of CD28 (Y123A) and CTLA-4 (Y139A),
as well as the Y201F mutant of CTLA-4, were generated by PCRB7-2 available for binding to CD28.
using the QuikChange site-directed mutagenesis kit (Stratagene).We have previously shown that the balance of CD28
After sequencing, the protein fusions were cloned into a mouseand CTLA-4 signals can determine not only the level but
stem cell virus (MSCV) retroviral vector, a gift from Dr. William Shaalso the composition and function of the emerging T cell
(Hawley et al., 1994).
response (Kuhns et al., 2000). Our findings here under- Day 3 activated T cells were infected with mixtures of CFP and
score the complexity of the dynamic mechanisms by YFP retroviruses, produced separately by transient transfections of
the Phoenix-E packaging line. To increase virus production, the cellswhich costimulatory signals mediated by CD28 and
were additionally transfected with plasmids encoding ecotropic en-CTLA-4 can orchestrate T cell responses at the level of
velope and gag-pol proteins, a gift from Dr. Michael Curran (UCindividual T cell clones. The relative levels of B7-2 and
Berkeley). Infection was performed by centrifugation at 1200g usingB7-1 on antigen-presenting cells is determined by the
filtered retroviral supernatants, supplemented with 4 g/ml poly-
activation status of the APC, which is influenced by brene (Sigma) and 25 mM HEPES (Irvine Scientific). Infected T cells
components of both the innate (toll-like receptors) and were used 2–4 days later.
acquired (cytokines and CD40/CD40L) immune sys-
tems. The degree to which CTLA-4 modulates the re- T Cell Staining and Flow Cytometry
sponse is in turn affected by the strength of the TCR A fusion of mouse B7-2 to human IgG1 (B7-2Ig) was produced using
signal, as well as the relative amounts of B7-1 and B7-2 an inducible Drosophila expression system (Zang et al., 2003). The
recombinant mouse B7-1/Fc chimera (B7-1Ig) was purchased fromavailable for binding. The preferential association of
R&D Systems, Inc.CTLA-4 with B7-1 and CD28 with B7-2, based on differ-
After incubation with the anti-Fc receptor antibody 24G2, 5C.C7ential avidities, provides for a previously unrecognized
CD28/ T cells infected with one of the YFP fusions were stained
level for fine tuning of stimulatory and inhibitory signals. with 50 g/ml B7-1Ig or B7-2Ig in PBS-2% FCS for 1 hr at 4C,
followed by a 30 min incubation with PE-conjugated anti-human Ig
Experimental Procedures Fc (Beckman Coulter). To compare protein surface levels, cells were
stained with 2 g/ml biotin-conjugated hamster anti-mouse CD28
Cells antibody (Caltag) or 2.5 g/ml biotin-conjugated hamster anti-
The mouse B10.A B cell lymphoma CH12.Lx (Arnold et al., 1983), a mouse CTLA-4 antibody (eBioscience) in PBS-2% FCS for 30 min
gift from Dr. William Sha (UC Berkeley), was subcloned, and a line at 4C, followed by a 30 min incubation with 1 g/ml PE-conjugated
with moderate to high expression levels of H2-I-Ek, B7-1, B7-2, and streptavidin (eBioscience). The cells were fixed in 4% parafolmalde-
ICAM-1 was selected. This line and the primary mouse T and B cells hyde and analyzed on EPICS XL-MCL analytical cytometer (Coulter).
were maintained in RPMI 1640 (BioWhittaker), supplemented with
10% fetal calf serum (FCS, Sigma), 2 mM L-glutamine (BioWhittaker),
Conjugate Formation and Fluorescence Microscopy100 U/ml penicillin and streptomycin (BioWhittaker), and 2 M
The CH12.Lx B cell lymphoma or activated B cells from wt B6,2-mercaptoethanol (Sigma). The packaging line Phoenix-E (Kinsella
B7-1/, B7-2/, or B7-1/B7-2/ mice were incubated for 5 hrand Nolan, 1996) was maintained in DMEM (BioWhittaker), supple-
either with 5 M MCC (CH12.Lx) or 10 g/ml OVA peptide (the re-mented with 10% FCS, 2 mM L-glutamine, and 100 U/ml penicillin
mainder). Conjugates between the peptide-pulsed APC and the T cellsand streptomycin.
were formed for 20 min at 37C, subsequent to which the cells were
adhered to Superfrost Plus positively charged slides for 5 min (Fisher
Mice, T and B Cell Activation Scientific), fixed in PBS-4% paraformaldehyde for 30 min, and per-
Recombination activating gene-deficient (RAG/) 5C.C7 (V11V3) mabilized with PBS-0.15% Triton X-100 (Sigma) for 3 min. Unreacted
TCR transgenic mice on the B10.A background (Taconic), which aldehyde groups were quenched with 0.25% NH4Cl and the cellsexpress a TCR specific for moth cytochrome c peptide MCC (88– were blocked overnight at 4C with PBS-5% normal donkey serum
103, ANERADLIAYLKQATK) in the context of H2-I-Ek, were bred to (NDS, Jackson Immunoresearch Laboratories). PKC  was visual-
homozygosity with B10.A CD28/ mice, a gift from Dr. Ron Schwartz ized by 1 hr incubation with rabbit polyclonal anti-PKC  antibody
(NIH), producing 5C.C7 CD28/ RAG/ animals. OT-II (V2V5) (C-18, Santa Cruz Biotechnology) in PBS-2% NDS, followed by 1
TCR transgenic RAG/ mice (Barnden et al., 1998), which express hr incubation with Cy3- or Cy5-conjugated donkey anti-rabbit serum
a TCR specific for hen egg ovalbumin peptide OVA (323–339, ISQAV (Jackson Immunoresearch Laboratories) in PBS-1% NDS. The cells
HAAHAEINEAGR) in the context of H2-I-Ab, were from Dr. William were washed and mounted in Slowfade Light antifade (Molecular
R. Heath (Royal Melbourne Hospital). B10.A, C57/BL6 (termed B6), Probes).
and B6 mice that were deficient either for CD80 (B7-1/), CD86 Cells were imaged on a Leica DMIRB/E inverted microscope using
(B7-2/), or both (B7-1/ B7-2/) were purchased from Jackson a 1.32 NA 63 objective. Fluorescence was excited with a 150W
Laboratories. All mice were bred and maintained in accordance with xenon arc lamp (Optiquip). CFP and YFP were detected with XF114
the animal care and use regulations of UC Berkeley. and XF30 filters (Omega Optical), respectively. Image stacks con-
5C.C7 or 5C.C7 CD28/ transgenic lymph node cells were stimu- sisting of 10–15 planes spaced 0.5 m were collected with a Quantix
lated with 5 M MCC peptide in the presence of irradiated (2000 CCD camera (Roper Scientific), operated by Slidebook software
rads) B10.A splenocytes. Similarly, OT-II transgenic lymph node (Intelligent Imaging Innovations). The image stacks were decon-
cells were stimulated with 10 g/ml OVA peptide in the presence volved using the nearest neighbor algorithm of Slidebook.
of irradiated B6 splenocytes. T cells were expanded in the presence
of 30 U/ml recombinant human IL-2 (Chiron) and infected with retro-
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